Prevents nausea and vomiting. ANDA 78127, held by Pharm Assoc. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 78127 (Ondansetron Hydrochloride), held by Pharm Assoc, was first approved by FDA on Jun 25, 2007, with 10 approved supplements and 0 published complete response letters.
Ondansetron oral solution is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron oral solution is also indicated for the prevention of postoperative nausea and/or vomiting.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 25, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 4MG BASE/5ML · solution;oral | Ondansetron Hydrochloride | Rx |
| Apr 3, 2026 | Supplement 14Manufacturing | Approved | None posted |
| Sep 17, 2025 | Supplement 12Labeling · Standard review | Approved | None posted |
| Sep 17, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Mar 7, 2018 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 27, 2017 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 27, 2017 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 29, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 25, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters